Nephrocare Health Services Limited, Asia’s largest dialysis network under the brand “NephroPlus,” announced its Financial Results for the second quarter and half year ended 30th September 2026. The company reported a robust performance with H1 FY27 revenue of ₹ 585.2 crore, an increase of 23.6% YoY, driven by treatments up 12.6% YoY to 21.01 lakh and guests up 9.6% YoY to 38,814, alongside a 9.7% YoY increase in revenue per treatment to ₹2,785.

Financial Highlights

The company’s H1 FY27 Adjusted EBITDA* stood at ₹ 134.4 crore, an increase of 15.3% YoY. The Adjusted PAT# grew 34.7% YoY to ₹76.1 crore, with a margin up 107 bps to 13.0%. The network expanded to 570 clinics across 6 countries with entry into Kazakhstan, making international business ~47% of revenue.

Operational Insights

Commenting on the Q2 & H1 FY27 results, Mr. Vikram Vuppala, Chairman & MD, said, “Dialysis market across the World continues to grow due to the increasing burden of Diabetes and Hypertension as well as improving access due to various interventions. NephroPlus continues to grow healthily in India and international markets and expect margins to remain in healthy range. We are excited to open NephroPlus in Kazakhstan, which will be our 6th market. The two clinics we acquired are a good starting point for us to better understand the local market nuances before we start scaling this network in Kazakhstan.”

As we enter new markets, margins and returns will move during the ramp-up. That’s the nature of building something new. But they will stay healthy, because our goal is clear: a scalable global dialysis platform built for the long term,” added Mr. Prashant Goenka, Chief Financial Officer.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Nephrocare Health Services Limited

Nephrocare Health Services Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Nephrocare moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 18 of recent sessions versus 12 for buyers, so the pressure has not fully lifted. Revenue grows at 33.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Nephrocare Health Services Limited.

Anthem Biosciences Limited (NSE: ANTHEM) has announced robust financial results for the second quarter and half year of FY27, showcasing significant growth and margin expansion. Consolidated revenue from operations for the quarter stood at ₹5,940 Mn, up 7.9% YoY, while EBITDA was ₹3,304 Mn, marking a 24.1% increase. The company’s profit after tax (PAT) for Q2FY27 was ₹2,115 Mn, reflecting a 21.9% rise compared to the same period last year.

Half-Year Financial Highlights

For the first half of FY27, Anthem Biosciences Limited reported consolidated revenue from operations of ₹10,123 Mn, a decrease of 7.2% YoY. However, the company’s EBITDA for H1 FY27 was ₹5,059 Mn, with margins at 46.2%. The PAT for H1 FY27 was ₹3,314 Mn, showing a 7.2% increase compared to H1 FY26.

Margin and Cost Efficiency

Anthem Biosciences Limited has demonstrated strong performance in maintaining and expanding its EBITDA and PAT margins. The company’s ability to sustain growth is attributed to strict discipline around cost efficiencies, yield optimization, and workforce productivity. This has further solidified its industry-leading margins, positioning the company well to sustain this performance throughout the year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Anthem posts a 5.8% three-month gain, but softens in the last few weeks. The PEG stands at 5.22 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 28.7% reflect exceptional pricing power and operational efficiency. The stock gives back 9.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 5.22 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.

Global Health Limited (NSE: MEDANTA), one of the largest private multi-specialty tertiary care providers in India, announced its unaudited consolidated financial results for the quarter and six-month period ending September 30, 2026. The company reported robust growth driven by significant bed additions and strong patient volumes. Notably, the company’s revenue from operations increased by 33.6% year-on-year to INR 14,690 million in Q2 FY27.

Key Financial Highlights

Operating EBITDA grew 60.2% year-on-year to INR 3,701 million with margins improving to 25.2% in Q2 FY27 compared to 21.0% in Q2 FY26. Profit after tax (PAT) stood at INR 2,191 million, up 38.3% year-on-year. The Noida hospital achieved EBITDA breakeven in Q2 FY27, within one year of commencing operations.

Operational Growth

The company added 74 new beds across the network during the quarter, with 49 beds added in Noida and 25 in Lucknow. The total census bed capacity stood at 3,115 in Q2 FY27 compared to 2,658 beds in Q2 FY26. In-patient count grew by 29.5% while out-patient count grew by 37.9% year-on-year. The occupancy rate increased to 67% compared to 64% in the same quarter last year.

Future Expansion Plans

Building on this momentum, the board approved the development of a 500-bedded super-specialty hospital in Ghaziabad, a market with strong demand for quality tertiary care. With this, the company plans to add over 3,450 beds across six greenfield projects to be executed over the next few years.

Commenting on the results, Mr. Pankaj Sahni, Group CEO and Director, said, ‘We are pleased to report strong growth in Q2 and H1 FY27, driven by robust patient volumes. We continue to deliver steady growth as we expand our bed capacity across multiple locations to meet India’s growing need for quality healthcare.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Global Health Limited

Global Health Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Global moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.08. The stock trades on brand and index weight, not on growth. The business compounds revenue at 17.2% and profits at 19.5% CAGR. That is strong double-digit growth on both counts. RSI stands at 29, well into oversold territory. Yet sellers still dominated on 21 of recent sessions versus 9 for buyers, so the pressure has not fully lifted. Revenue grows at 17.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Global Health Limited.